2016 American Transplant Congress
Pharmakokinetics of Prolonged-Release Formulation of Tacrolimus: Comparison of AUC0-24 and Concentration at 10 Time Points.
Background:Use of an appropriate immunosuppressant is necessary for good graft survival in kidney transplantation (KTx). Currently, a prolonged-release formulation of tacrolimus (Graceptor or Adovagraf, Astellas…2016 American Transplant Congress
Calcineurin Inhibitor (CNI) Nephrotoxicity Is Mediated by Defective Amp-Activated Protein Kinase (AMPK) Activation.
Medicine, UAB, Birmingham, AL.
Background: CNIs are potent immunosuppressant therapies, but associated with nephrotoxicity manifested by interstitial fibrosis and progressive graft dysfunction. AMPK is a major sensor and regulator…2016 American Transplant Congress
Novel Nuclear Factor-κB Activation Inhibitor, Dehydroxymethylepoxyquinomicin, Prevents the Development of Chronic Cyclosporine Nephropathy in Rats.
Purpose:The nephrotoxicity of the calcineurin inhibitors including cyclosporine is a major problem in the kidney transplantation. We investigated the effect of a novel nuclear factor-κB…2016 American Transplant Congress
Genomic-Derived Markers to Identify Calcineurin Inhibitor Nephrotoxicity in Pediatric Kidney Transplant Recipients.
Background:Calcineurin inhibitor nephrotoxicity (CNIT) is a well-known contributor to chronic allograft dysfunction in kidney transplant recipients (KTRs). Pediatric KTRs are particularly at risk given their…2016 American Transplant Congress
Adding an Antimetabolite to a Calcineurin-Inhibitor-Based Immunosuppression Regimen Leads to Improved Native Renal Function After Liver Transplantation.
Surgery, University of Wisconsin, Madison, WI.
Background: Nephrotoxic side effects of calcineurin inhibitors (CNI) have been well established. The addition of anti-metabolites (AM) to CNI-based immunosuppression (IS) regimens has been proposed…2016 American Transplant Congress
Tacrolimus Precision Medicine: Antibiotics Increase Intra-Patient Variability in Tacrolimus Trough Concentrations in Kidney Transplant Recipients.
Medicine/Nephrology and Hyeprtension, Weill Cornell Medical College, New York, NY.
BACKGROUND. The gut microbiome impacts drug absorption, metabolism, and distribution and was recently shown to be associated with tacrolimus dosing requirements. Since antibiotics can alter…2015 American Transplant Congress
Basiliximab Induction With Delayed Tacrolimus Initiation up to 14 Days Post Liver Transplantation Maintains Excellent Clinical Outcomes While Preserving Renal Function
University of Virginia Health System, Charlottesville, VA.
Background: Calcineurin inhibitors are frequently delayed to allow for recovery of renal function after transplantation; however, there is a paucity of literature supporting a delay…2015 American Transplant Congress
Calcineurin Inhibitor-Free Immunossupresion After Kidney Transplantation, Using Everolimus De Novo – Single Center Experience
The aim of the study was to analyse the clinical outcome in kidney transplant recipients treated with CNI (calcineurin inhibitors)-free protocol versus kidney transplant recipients…2015 American Transplant Congress
Primary and Secondary Vaccine Responses in a Non-Human Primate Model of Cardiac Allotransplantation
Purpose: To compare the effect of calcineurin- versus costimulation-based immunosuppression on primary and secondary vaccine responses in non-human primate heart transplant recipients.Background: Antibody response following…2015 American Transplant Congress
Intrapatient Variability of Tacrolimus Blood Concentrations Following Renal Transplant – Acute Rejection or No Connection?
Background: A high degree of intrapatient variability (IPV) of tacrolimus blood concentrations has been associated with poor long-term outcome (1). Periods of under-exposure with increased…
American Transplant Congress abstracts